Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C714R
- Development stage
- Unknown
- Lead developer
- AJU Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
C714R is a reference formulation of a drug evaluated in bioequivalence studies against AJU-C714, developed by Aju Pharm. It is being studied in healthy adult volunteers for safety and pharmacokinetic characteristics, primarily as part of clinical research involving comparisons with AJU-C714. The detailed mechanism of action or active ingredient of C714R is not specified in publicly available sources, but context suggests it may be related to antidiabetic or dyslipidemia therapy, likely as a dipeptidyl peptidase-4 (DPP-4) inhibitor, reflecting the mechanism of action of related pipeline drugs by the same developer[1][3][5][7][10].
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on C714R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C714R.